These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1290 related articles for article (PubMed ID: 33909933)

  • 1. Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
    Abeykoon JP; Zanwar S; Ansell SM; Muchtar E; He R; Greipp PT; King RL; Ailawadhi S; Paludo J; Larsen JT; Habermann TM; Inwards D; Go RS; Thanarajasingam G; Buadi F; Dispenzieri A; Thompson CA; Witzig TE; Lacy M; Gonsalves W; Nowakowski GS; Dingli D; Rajkumar SV; Kyle RA; Sher T; Roy V; Rosenthal A; Chanan-Khan AA; Reeder C; Gertz MA; Kumar S; Kapoor P
    Am J Hematol; 2021 Aug; 96(8):945-953. PubMed ID: 33909933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
    Kapoor P; Paludo J; Abeykoon JP
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of consensus panel 1 from the 11
    Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
    Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
    Castillo JJ; Meid K; Flynn CA; Chen J; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Yang G; Hunter Z; Treon SP
    Blood Adv; 2020 Aug; 4(16):3952-3959. PubMed ID: 32822482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
    Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
    Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
    Gavriatopoulou M; García-Sanz R; Kastritis E; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Sonneveld P; Dimopoulos MA
    Blood; 2017 Jan; 129(4):456-459. PubMed ID: 27872060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
    Trotman J; Buske C; Tedeschi A; Matous JV; MacDonald D; Tam CS; Tournilhac O; Ma S; Treon SP; Oriol A; Ping J; Briso EM; Arango-Hisijara I; Dimopoulos MA
    Clin Cancer Res; 2021 Nov; 27(21):5793-5800. PubMed ID: 34380643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of MYD88
    Zanwar S; Abeykoon JP; Durot E; King R; Perez Burbano GE; Kumar S; Gertz MA; Quinquenel A; Delmer A; Gonsalves W; Cornillet-Lefebvre P; He R; Warsame R; Buadi FK; Novak AJ; Greipp PT; Inwards D; Habermann TM; Micallef I; Go R; Muchtar E; Kourelis T; Dispenzieri A; Lacy MQ; Dingli D; Nowakowski G; Thompson CA; Johnston P; Thanarajasingam G; Bennani NN; Witzig TE; Villasboas J; Leung N; Lin Y; Kyle RA; Rajkumar SV; Ansell SM; Le-Rademacher JG; Kapoor P
    Am J Hematol; 2020 Mar; 95(3):274-281. PubMed ID: 31814157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
    J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.